The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed, and funded by an Alkermes company.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 103 results
Sort by date: Descending
Sep 2013
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness
Addiction
AUTHOR(S)

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL

View on PubMed
Clinical
Opioid Use Disorder
Mar 2013
Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study
NeuroImage
AUTHOR(S)

Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM

View on PubMed
Clinical
Alcohol Use Disorder
Nov 2012
Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection
Journal of Studies on Alcohol and Drugs
AUTHOR(S)

Mitchell MC, Memisoglu A, Silverman BL

View on PubMed
Clinical
Opioid Use Disorder
Sep 2011
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence
Alcoholism: Clinical and Experimental Research
AUTHOR(S)

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR

View on PubMed
Clinical
Alcohol Use Disorder
May 2011
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence
The American Journal of Managed Care
AUTHOR(S)

Baser O, Chalk M, Rawson R, Gastfriend DR

View on PubMed
Real World Evidence
Alcohol Use Disorder
Apr 2011
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
The Lancet
AUTHOR(S)

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL

View on PubMed
Clinical
Opioid Use Disorder
Aug 2010
Impact of treatment with intramuscular injectable extended-release naltrexone on counseling and support group participation in patients with alcohol dependence
Journal of Addiction Medicine
AUTHOR(S)

Cisler RA, Silverman BL, Gromov I, Gastfriend DR

View on PubMed
Clinical
Alcohol Use Disorder
Mar 2008
Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics
Alcoholism: Clinical and Experimental Research
AUTHOR(S)

Lucey MR, Silverman BL, Illeperuma A, O'Brien CP

View on PubMed
Clinical
Alcohol Use Disorder
Feb 2008
Early treatment response in alcohol dependence with extended-release naltrexone
The Journal of Clinical Psychiatry
AUTHOR(S)

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM

View on PubMed
Clinical
Alcohol Use Disorder
Nov 2007
Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence
Journal of Studies on Alcohol and Drugs
AUTHOR(S)

Dunbar JL, Turncliff RZ, Hayes SC, Farrell CB

View on PubMed
Clinical
Alcohol Use Disorder